The Food and Drug Administration (FDA) lifted restrictions on mifepristone, a drug approved for use in medical abortions, on Thursday.

The decision authorizes doctors to prescribe the drugs online and mail the pills, allowing women to perform early abortions — up to ten weeks of gestation — without leaving their homes. The FDA first approved mifepristone, which is paired with another drug called misoprostol, for earlier abortions in 2000.

The FDA announced two changes: “Removing the requirement that mifepristone be dispensed only in certain healthcare settings, specifically clinics, medical offices, and hospitals” also known as the “in-person dispensing requirement,” and “adding a requirement that pharmacies that dispense the drug be certified.”

Taken by pill, this type of abortion is also referred to as abortion with pills, chemical abortion, medication abortion, and telemedicine abortion….

According to the U.S. Centers for Disease Control’s most recent Abortion Surveillance report, for the year 2019, “early medical abortions” made up 42.3% of abortions that year….

In anticipation of the FDA’s decision, Charlotte Lozier Institute, the research arm of the Susan B. Anthony List, released a new study finding increased access to abortion pills a public health risk in November.

“The rate of abortion-related emergency room visits following a chemical abortion increased over 500% from 2002 through 2015, according to an analysis of Medicaid claims data,” the press release read. “Over the same period, chemical abortions within the study population increased from 4.4% to 34.1% of total abortions.”

The study also found that the rate of abortion-related emergency-room visits is increasing faster for chemical abortions than for surgical abortions and that chemical abortion makes subsequent abortions more dangerous.

The above comes from a Dec. 16 story in Angelus News.